Loading…
Lobbying Spend
—
Filings
17
Firms Hired
1
Active Period
2002–2009
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Client expense: — · Firm income: $30,000
Matched citations: S. 726
Access to Life-Saving Medicine Act
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1038
Access to Life-Saving Medicine Act
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1038
Access to Life-Saving Medicine Act
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1038
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: HR 1956
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: HR 1956
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: HR 1956
Pathway for Biosimilars Act
2008 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: — · Firm income: $30,000
Matched citations: HR 5629
Source: Senate LDA